<DOC>
	<DOCNO>NCT00784550</DOCNO>
	<brief_summary>The purpose study determine efficacy safety combination ADVAIR DISKUS® 250/50mcg ( FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT ) plus SPIRIVA® HANDIHALER® inhaler 18mcg ( TIOTROPIUM ) compare SPIRIVA® HANDIHALER® inhaler 18mcg ( TIOTROPIUM ) patient COPD . SPIRIVA® HANDIHALER® trade mark Boehringer Ingelheim Pharma GmbH &amp; Co. KG . ADVAIR DISKUS® register trademark GSK group company .</brief_summary>
	<brief_title>A 24-Week Study Evaluate Safety Efficacy ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler Subjects With Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>COPD diagnosis At least 10 pack year smoke history Postalbuterol FEV1 great equal 40 % less equal 80 % predict normal An FEV1/FVC ratio less equal 0.70 Current diagnosis asthma Other respiratory disorder COPD Abnormal clinical significant ECG Chest xray clinically significant abnormality believe due COPD Body Mass Index great equal 40/kg/m2 Use Long Term Oxygen Therapy Lung resection surgery Women pregnant lactate Visit 1 Previously diagnose cancer unless complete remission 2 year Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Spirometry</keyword>
	<keyword>COPD</keyword>
</DOC>